InvestSMART

Neuren Pharmaceuticals Limited (ASX: NEU) - Announcements

Current share price for NEU : $16.740 0.26 (1.53%)+

ASX company news and announcements for Neuren Pharmaceuticals Limited (NEU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neuren Pharmaceuticals Limited (NEU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neuren Pharmaceuticals Limited (NEU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neuren Pharmaceuticals Limited (NEU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,122 Update - Notification of buy-back - NEU 13 Mar 2026 8:26AM $11.950 $16.740 risen by 40.08%
$2,122 Update - Notification of buy-back - NEU 10 Mar 2026 8:40AM $11.680 $16.740 risen by 43.32%
$2,122 Change of Director's Interest Notice - J Basile 6 Mar 2026 10:25AM $12.590 $16.740 risen by 32.96%
$2,122 Update - Notification of buy-back - NEU 4 Mar 2026 8:42AM $12.560 $16.740 risen by 33.28%
$2,122 Acadia confirms plan to request CHMP re-examination 3 Mar 2026 9:50AM $13.770 $16.740 risen by 21.57%
$2,122 Investor presentation, 27 February 2026 27 Feb 2026 11:54AM $13.480 $16.740 risen by 24.18%
$2,122 2025 royalty income A$65m, profit after tax A$30m 27 Feb 2026 9:59AM $13.440 $16.740 risen by 24.55%
$2,122 Appendix 4E and 2025 full year accounts 27 Feb 2026 9:53AM $13.440 $16.740 risen by 24.55%
$2,122 Acadia reports DAYBUE net sales for 2025 and 2026 guidance 26 Feb 2026 11:15AM $12.710 $16.740 risen by 31.71%
$2,122 Pause in Trading 26 Feb 2026 9:53AM $12.710 $16.740 risen by 31.71%
$2,122 Update - Notification of buy-back - NEU 13 Feb 2026 9:32AM $13.570 $16.740 risen by 23.36%
$2,122 Notification of buy-back - NEU 11 Feb 2026 6:24PM $13.430 $16.740 risen by 24.65%
$2,122 Notification of Neuren investor webinar on 12 February 2026 11 Feb 2026 5:05PM $13.430 $16.740 risen by 24.65%
$2,122 Neuren to commence new on-market share buy-back program 11 Feb 2026 5:00PM $13.430 $16.740 risen by 24.65%
$2,122 First patient dosed in Neuren PMS Phase 3 trial 6 Feb 2026 9:26AM $13.200 $16.740 risen by 26.82%
$2,122 Priority Review Voucher program reauthorized by US Congress 5 Feb 2026 8:11AM $14.630 $16.740 risen by 14.42%
$2,122 Neuren receives US FDA meeting feeback for HIE and PTHS 4 Feb 2026 5:07PM $14.630 $16.740 risen by 14.42%
$2,122 Trading Halt 4 Feb 2026 10:14AM $14.630 $16.740 risen by 14.42%
$2,122 Pause in Trading 4 Feb 2026 9:57AM $14.630 $16.740 risen by 14.42%
$2,122 Acadia provides update on EU regulatory submission 3 Feb 2026 9:40AM $16.250 $16.740 risen by 3.02%
$2,122 Response to ASX Aware Letter 19 Jan 2026 9:10AM $19.140 $16.740 fallen by 12.54%
$2,122 DAYBUE net sales projected to reach approx US$700m in 2028 14 Jan 2026 10:26AM $19.930 $16.740 fallen by 16.01%
$2,122 NNZ-2591 PMS Phase 2 trial published in Neurology Genetics 7 Jan 2026 10:20AM $18.990 $16.740 fallen by 11.85%
$2,122 Health Canada approves Clinical Trial Application for Koala 22 Dec 2025 9:48AM $19.590 $16.740 fallen by 14.55%
$2,122 FDA approves DAYBUE STIX (trofinetide), powder formulation 15 Dec 2025 9:05AM $19.010 $16.740 fallen by 11.94%

26 - 50 of 821 results

Page 2 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.